Status | Study |
Completed |
Study Name: Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition Condition: Multiple Sclerosis, Relapsing-Remitting Date: 2015-11-04 |
Completed |
Study Name: Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012 Condition: Multiple Sclerosis, Relapsing-Remitting Date: 2015-10-16 Interventions: Drug: dimethyl fumarate dimethyl fumarate administered as per the arm description |
Active, not recruiting |
Study Name: Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Condition: Multiple Sclerosis, Relapsing-Remitting Date: 2015-09-17 Interventions: Drug: dimethyl fumarate administered orally Other Na |
Enrolling by invitation |
Study Name: Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS) Condition: Multiple Sclerosis, Relapsing-Remitting Date: 2015-07-02 Interventions: Drug: Domperidone Addition of Domperidone to current Disease Modifying Therapy. |
Recruiting |
Study Name: Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis Condition: Multiple Sclerosis, Relapsing-Remitting Date: 2015-05-27 Interventions: Drug: Dimethyl fumarate Dimethyl fumarate (Tecfidera®) treatment is initiated by daily administrati |
Withdrawn |
Study Name: Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis Condition: Relapsing Remitting Multiple Sclerosis Date: 2015-05-11 Interventions: Drug: dimethyl fumarate dimeth |
Terminated |
Study Name: A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis Condition: Multiple Sclerosis, Relapsing-Remitting Date: 2015-04-02 Interventions: Biological: Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the fla |
Completed |
Study Name: Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya� With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM Condition: Multiple Sclerosis, Relapsing-Remitting Date: 2015-01-08 Interventions: Interventional |
Completed |
Study Name: Rebif® Rebidose® Versus Rebiject II® Ease-of-Use Condition: Multiple Sclerosis, Relapsing-Remitting Date: 2013-12-18 Interventions: Device: Rebif Rebidose Rebif 4 |
Terminated |
Study Name: A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Condition: Multiple Sclerosis, Relapsing-Remitting Date: 2013-03-07 Interventions: Drug: Part A: 100 mg/mL GSK2618960 |